These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 18367383)

  • 41. In vitro antifungal susceptibility of Scopulariopsis brevicaulis isolates.
    Skóra M; Macura AB; Bulanda M
    Med Mycol; 2014 Oct; 52(7):723-7. PubMed ID: 25049036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trichophyton species susceptibility to green and red propolis from Brazil.
    Siqueira AB; Gomes BS; Cambuim I; Maia R; Abreu S; Souza-Motta CM; de Queiroz LA; Porto AL
    Lett Appl Microbiol; 2009 Jan; 48(1):90-6. PubMed ID: 19018958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses.
    Clayton YM
    Br J Dermatol; 1994 Apr; 130 Suppl 43():7-8. PubMed ID: 8186143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility.
    Carrillo-Muñoz AJ; Fernández-Torres B; Cárdenes DC; Guarro J
    Chemotherapy; 2003 Sep; 49(5):248-51. PubMed ID: 14504436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii.
    Zhang X; Huang H; Feng P; Zhang J; Zhong Y; Xue R; Xie Z; Li M; Xi L
    Eur J Dermatol; 2011; 21(4):573-6. PubMed ID: 21865116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activities of antifungal agents against clinical isolates of dermatophytes from animals.
    Itoi S; Kano R; Hasegawa A; Kamata H
    J Vet Med Sci; 2012 Aug; 74(8):1067-9. PubMed ID: 22467073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.
    Ghannoum MA; Chaturvedi V; Espinel-Ingroff A; Pfaller MA; Rinaldi MG; Lee-Yang W; Warnock DW
    J Clin Microbiol; 2004 Jul; 42(7):2977-9. PubMed ID: 15243047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Non-dermatophytes in onychomycosis of the toenails.
    Ellis DH; Watson AB; Marley JE; Williams TG
    Br J Dermatol; 1997 Apr; 136(4):490-3. PubMed ID: 9155945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of disk diffusion method and broth microdilution method for antifungal susceptibility testing of dermatophytes.
    Esteban A; Abarca ML; Cabañes FJ
    Med Mycol; 2005 Feb; 43(1):61-6. PubMed ID: 15712608
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi.
    McGinnis MR; Pasarell L
    Med Mycol; 1998 Aug; 36(4):243-6. PubMed ID: 9776842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China.
    Li RY; Wan Z; Wang AP; Shen YN; Lu CM; Li M; Xi LY; Liu WD; Zeng FQ
    Mycoses; 2004 Oct; 47(9-10):402-6. PubMed ID: 15504124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature.
    Gupta AK; Gregurek-Novak T; Konnikov N; Lynde CW; Hofstader S; Summerbell RC
    J Cutan Med Surg; 2001; 5(3):206-10. PubMed ID: 11685666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.
    ZHANG JM; XI LY; ZHANG H; XIE Z; SUN JF; LI XQ; LU S
    Eur J Dermatol; 2009; 19(5):451-5. PubMed ID: 19502155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison between the standardized clinical and laboratory standards institute M38-A2 method and a 2,3-Bis(2-Methoxy-4-Nitro-5-[(Sulphenylamino)Carbonyl]-2H-tetrazolium hydroxide- based method for testing antifungal susceptibility of dermatophytes.
    Shehata AS; Mukherjee PK; Ghannoum MA
    J Clin Microbiol; 2008 Nov; 46(11):3668-71. PubMed ID: 18832129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An update on antifungal resistance in dermatophytosis.
    Gupta AK; Mann A; Polla Ravi S; Wang T
    Expert Opin Pharmacother; 2024 Apr; 25(5):511-519. PubMed ID: 38623728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum.
    Azambuja CV; Pimmel LA; Klafke GB; Xavier MO
    An Bras Dermatol; 2014; 89(4):581-6. PubMed ID: 25054744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fusarium spp. as agents of onychomycosis in immunocompetent hosts.
    Guilhermetti E; Takahachi G; Shinobu CS; Svidzinski TI
    Int J Dermatol; 2007 Aug; 46(8):822-6. PubMed ID: 17651164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.
    Ghannoum M; Isham N; Long L
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5154-8. PubMed ID: 26055386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro activity of posaconazole against clinical isolates of dermatophytes.
    Barchiesi F; Arzeni D; Camiletti V; Simonetti O; Cellini A; Offidani AM; Scalise G
    J Clin Microbiol; 2001 Nov; 39(11):4208-9. PubMed ID: 11682563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day.
    De Backer M; De Vroey C; Lesaffre E; Scheys I; De Keyser P
    J Am Acad Dermatol; 1998 May; 38(5 Pt 3):S57-63. PubMed ID: 9594939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.